AUA 2018: Predictors of Poor Functional Outcomes after Focal High Intensity Focused Ultrasound

San Francisco, CA (UroToday.com) Data from 625 patients in the UK focal High Intensity Focused Ultrasound (HIFU) registry were analyzed to evaluate for predictors of functional outcomes following treatment. Poor functional outcomes following focal ablative therapy, including HIFU, are rare. It is therefore important to endeavor to understand what factors might lead to poor functional outcomes in some men.

AUA 2018: ADT Increased the Risk of Pulmonary Embolism in Patients with Prostate Cancer - Taiwan National Health Insurance Research Database

San Francisco, CA (UroToday.com) Androgen deprivation therapy (ADT) is a standard treatment for men with metastatic prostate cancer. There are several known potential side-effects of ADT, such as weight gain, metabolic syndrome, hot flashes, and decreased bone density.  Jian-Hua Hong from National Taiwan University Hospital presented his group’s work looking at the association between ADT and pulmonary embolism (PE).

AUA 2018: Association of Dose Reduction of Abiraterone Acetate plus Prednisone or Enzalutamide and PSA Progression in Veterans with mCRPC

San Francisco, CA (UroToday.com) Abiraterone acetate and enzalutamide are oral agents which have both been shown to reduce PSA, delay time to PSA progression, and prolong overall survival in men with metastatic castrate-resistant prostate adenocarcinoma (mCRPC).  Stephen Freedland, MD,  from Cedars-Sinai Medical Center, presented his group’s data evaluating the association between the dose reduction of these agents, which can sometimes be necessary in order to minimize side-effects or toxicities, and PSA progression in men with mCRPC. 

AUA 2018: Impact of Lymph Node Count and Adjuvant Therapy on Oncologic Outcomes in Node Positive Patients with Prostate Cancer

San Francisco, CA (UroToday.com) In this abstract, Selma Masic, MD and colleagues evaluated the associations between oncologic outcomes and nodal count in patients with positive nodes at radical prostatectomy.  Additionally, they sought to determine if there was an association between adjuvant therapy in node positive patients that improved oncologic outcomes.  Pelvic lymph node dissection is the most definitive lymph node staging modality for prostate cancer.  While newer imaging methods are actively being investigated, previous studies have demonstrated that existing imaging with CT and MRI have low sensitivity.

AUA 2018: Prospective Evaluation of Effect on Intraocular Pressure and Visual Function in Patients Without and with Ophthalmic Diseases after Robotic Assisted Laparoscopic Prostatectomy

San Francisco, CA (UroToday.com) In this abstract Shigenori Kakutani, MD discussed ophthalmic changes from robotic-assisted laparoscopic prostatectomy.  Previous publications have demonstrated the increase in intraocular pressure from the steep Trendelenburg position with subsequent concerns over the potential postoperative visual loss.  Few data have investigated ophthalmic disease following prostatectomy specifically. 

AUA 2018: Which Patients with Low Risk Prostate Cancer Are Still Receiving Radical Prostatectomy? Impact of Patient Selection on Inverse Stage Migration

San Francisco, CA (UroToday.com) The increasing utilization of conservative approaches such as active surveillance in select patients with low risk prostate cancer substantially reduce the proportion of patients with favorable disease characteristics undergoing radical prostatectomy.  In this study, the authors sought to describe the stage migration towards more aggressive disease characteristics in patients treated by radical prostatectomy.

AUA 2018: Comparative Effectiveness of Neoadjuvant and Adjuvant Chemotherapy in the Medicare Bladder Cancer Population

San Francisco, CA (UroToday.com) Neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) prior to radical cystectomy (RC) is supported by Level 1 evidence; yet utilization is not as high as it should be, due to multiple concerns – specifically, delay to RC, complications from chemotherapy, concern for renal function deterioration, etc. On the other hand, there is no strong data to support adjuvant therapy (AC), as of yet – though, there are indicators to suggest it may be effective.